Schmitt M - Search Results

1

uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.

Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, von Minckwitz G, Thomssen C, Harbeck N. Annecke K, et al. Among authors: schmitt m. Adv Clin Chem. 2008;45:31-45. doi: 10.1016/s0065-2423(07)00002-9. Adv Clin Chem. 2008. PMID: 18429492 Review.

2

Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.

Schmitt M, Jänicke F, Moniwa N, Chucholowski N, Pache L, Graeff H. Schmitt M, et al. Biol Chem Hoppe Seyler. 1992 Jul;373(7):611-22. doi: 10.1515/bchm3.1992.373.2.611. Biol Chem Hoppe Seyler. 1992. PMID: 1515091 Review.

3

[Flow cytometry DNA analysis of pure cell nuclei from formalin fixed paraffin sections in primary breast cancer: correlation with other prognostic factors].

Harbeck N, Moniwa N, Busch E, Schmitt M, Jänicke F, Fellbaum C, Höfler H, Graeff H. Harbeck N, et al. Among authors: schmitt m. Gynakol Rundsch. 1991;31 Suppl 2:299-302. Gynakol Rundsch. 1991. PMID: 1790958 German. No abstract available.

4

Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.

Schmitt M, Goretzki L, Jänicke F, Calvete J, Eulitz M, Kobayashi H, Chucholowski N, Graeff H. Schmitt M, et al. Biomed Biochim Acta. 1991;50(4-6):731-41. Biomed Biochim Acta. 1991. PMID: 1801751

5

Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.

Schmitt M, Kanayama N, Jänicke F, Hafter R, Graeff H. Schmitt M, et al. Adv Exp Med Biol. 1991;297:111-28. doi: 10.1007/978-1-4899-3629-5_10. Adv Exp Med Biol. 1991. PMID: 1837419

6

Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.

Schmitt M, Jänicke F, Graeff H. Schmitt M, et al. Blood Coagul Fibrinolysis. 1990 Dec;1(6):695-702. Blood Coagul Fibrinolysis. 1990. PMID: 2133250

7

Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.

Reuning U, Wilhelm O, Nishiguchi T, Guerrini L, Blasi F, Graeff H, Schmitt M. Reuning U, et al. Among authors: schmitt m. Nucleic Acids Res. 1995 Oct 11;23(19):3887-93. doi: 10.1093/nar/23.19.3887. Nucleic Acids Res. 1995. PMID: 7479032 Free PMC article.

8

Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.

Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Jänicke F, Höfler H, Graeff H. Schmalfeldt B, et al. Among authors: schmitt m. Cancer Res. 1995 Sep 15;55(18):3958-63. Cancer Res. 1995. PMID: 7664262

9

Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.

Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F, Graeff H. Kuhn W, et al. Among authors: schmitt m. Gynecol Oncol. 1994 Dec;55(3 Pt 1):401-9. doi: 10.1006/gyno.1994.1313. Gynecol Oncol. 1994. PMID: 7835780

10

[Development of a technique for isolation of intact tumor cells from fresh breast or ovarian cancer tissue. Use in analysis of tumor-associated proteolytic factors].

Harbeck N, Schüren E, Yamamoto N, Schmitt M, Höfler H, Graeff H. Harbeck N, et al. Among authors: schmitt m. Gynakol Geburtshilfliche Rundsch. 1993;33 Suppl 1:277-9. doi: 10.1159/000272263. Gynakol Geburtshilfliche Rundsch. 1993. PMID: 8118313 German. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,983 results

Search Page

Filters